{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Abbreviation or Term\u00b9', 'Definition/Explanation', 'QD', 'Once daily', 'QTc', 'QT interval corrected', 'QTcF', 'QT interval corrected using Frederichia equation', 'SAE', 'Serious adverse event', 'SD', 'Standard deviation or stable disease', 'T12', 'Terminal elimination half-life', 'T3', 'Triiodothyronine', 'T4', 'Thyroxine', 'Tmax', 'Time of maximum observed concentration', 'TID', 'Three times daily', 'TSH', 'Thyroid-stimulating hormone', 'ULN', 'Upper limit of normal', 'ULQ', 'Upper limit of quantitation', 'UV', 'Ultraviolet', 'WBC', 'White blood cell', 'WOCBP', 'Women of childbearing potential', 'WONCBP', 'Women of nonchildbearing potential', '1', 'All of these abbreviations may or may not be used in protocol.', 'Page 6 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'PROTOCOL SIGNATURE', 'I confirm that I have read this protocol, and I will conduct the study as outlined herein and', 'according to the ethical principles stated in the latest version of the Declaration of Helsinki, the', 'applicable ICH guidelines for good clinical practice, and the applicable laws and regulations of the', 'federal government. I will promptly submit the protocol to the IRB for review and approval. Once', 'the protocol has been approved by the IRB, I understand that any modifications made during the', 'study must first be approved by the IRB prior to implementation except when such modification', 'is made to remove an immediate hazard to the subject.', 'I will provide copies of the protocol and all pertinent information to all individuals responsible to', 'me who assist in the conduct of this study. I will discuss this material with them to ensure that they', 'are fully informed regarding the study treatment, the conduct of the study, and the obligations of', 'confidentiality.', 'This document is signed electronically through submission and approval by the Principal', 'Investigator at Huntsman Cancer Institute in the University of Utah IRB Electronic Research', 'Integrity and Compliance Administration (ERICA) system. For this reason, the Principal', 'Investigator at Huntsman Cancer Institute will not have a hand-written signature on this signature', 'page.', 'Instructions to multi-site Principal Investigators at locations other than Huntsman Cancer Institute:', 'SIGN and DATE this signature page and PRINT your name. Return the original, completed and', 'signed, to the HCI Research Compliance Office. Retain a copy in the regulatory binder.', 'Signature of Principal Investigator', 'Date', 'Principal Investigator Name (Print)', 'Name of Institution', 'Page 7 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'STUDY SUMMARY', 'Title', 'A Randomized Phase II Clinical Trial of ADT', 'Combined with Abiraterone or Docetaxel in', 'Metastatic Hormone Sensitive Prostate Cancer.', 'Short Title', 'ACADEMIC', 'Protocol Identifiers (IRB - internal)', 'IRB 115099 - HCI-18-GU-11', 'IND number', 'Exempt', 'Phase', 'Phase II', 'Design', 'This is an open label, randomized prospective', 'study of ADT + Abiraterone vs. ADT +', 'Docetaxel in men with metastatic hormone', 'sensitive prostate cancer.', 'Study Duration', 'This study is expected to enroll for 24 months.', 'Patients will be followed for 18 months or until', 'disease progression, whichever occurs first. It', 'will take approximately 3.5 years to complete', 'the study.', 'Study Center(s)', 'This will be a multi-institution trial conducted at', 'the Huntsman Cancer Institute, at the University', 'of Utah. Up to 7 additional centers may be', 'opened.', 'Objectives', 'The primary objective of this study is to assess', 'the difference in QOL from baseline to month', '12 between ADT + Docetaxel vs ADT +', 'Abiraterone.', 'Number of Subjects', '89 patients will be enrolled. Patients will be', 'randomized 1:1 to each treatment arm.', 'Diagnosis and Main Eligibility Criteria', '- Male subject aged > 18 years.', '- Histologically diagnosed adenocarcinoma of', 'the prostate by WHO.', '- Radiographically confirmed metastatic disease', 'prior to patient enrollment. Metastatic disease', 'can be confirmed based on conventional', 'imaging (CT, MRI, nuclear medicine bone scan)', 'or molecular imaging (fluciclovine-PET/CT', 'PSMA-PET/CT, Choline-PET/CT etc).', '- ECOG 2.', '- Prior therapy with ADT or first generation', 'anti-androgen receptor therapy (example:', 'bicalutamide) is allowed.', '- Prior abiraterone or docetaxel use for', 'metastatic hormone sensitive prostate cancer is', 'not allowed.', 'Page 8 of 52']\n\n###\n\n", "completion": "END"}